603707 健友股份
交易中 10-19 09:39:43
资讯
新帖
简况
股市必读：健友股份（603707）10月14日董秘有最新回复
证券之星 · 10-15
股市必读：健友股份（603707）10月14日董秘有最新回复
股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》
证券之星 · 10-08
股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》
健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%
证券之星 · 09-29
健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
央广财经 · 09-28
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准
智通财经 · 09-28
健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准
股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》
证券之星 · 09-28
股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》
健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%
证券之星 · 09-24
健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》
证券之星 · 09-24
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》
健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件
同花顺 · 09-22
健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件
股市必读：健友股份（603707）9月15日董秘有最新回复
证券之星 · 09-16
股市必读：健友股份（603707）9月15日董秘有最新回复
健友股份：FDA认证产线支撑自有品种快速放量
证券之星 · 09-15
健友股份：FDA认证产线支撑自有品种快速放量
每周股票复盘：健友股份（603707）子公司获FDA阿达木单抗新增产线批件
证券之星 · 09-06
每周股票复盘：健友股份（603707）子公司获FDA阿达木单抗新增产线批件
健友股份：股价受宏观环境、行业周期、市场情绪等多重因素影响
证券之星 · 09-04
健友股份：股价受宏观环境、行业周期、市场情绪等多重因素影响
健友股份：XTMAB‑16 已完成 II 期临床试验，2026年已正式进入 III 期临床阶段
证券之星 · 09-04
健友股份：XTMAB‑16 已完成 II 期临床试验，2026年已正式进入 III 期临床阶段
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》
证券之星 · 09-03
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》
健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式
证券之星 · 09-02
健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式
健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%
证券之星 · 09-01
健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%
股市必读：健友股份新发布《健友股份2026年半年度报告摘要》
证券之星 · 08-31
股市必读：健友股份新发布《健友股份2026年半年度报告摘要》
每周股票复盘：健友股份（603707）Q2净利降51.11%
证券之星 · 08-30
每周股票复盘：健友股份（603707）Q2净利降51.11%
健友股份（603707）2026年中报简析：净利润同比下降34.48%
证券之星 · 08-29
健友股份（603707）2026年中报简析：净利润同比下降34.48%
公司概况
公司名称：
南京健友生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-07-19
主营业务：
南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。
发行价格：
7.21
{"stockData":{"symbol":"603707","market":"SH","secType":"STK","nameCN":"健友股份","latestPrice":8.19,"timestamp":1792373983000,"preClose":8.15,"halted":0,"volume":2716900,"delay":0,"changeRate":0.0049,"floatShares":1616000000,"shares":1616000000,"eps":0.2989,"marketStatus":"交易中","change":0.04,"latestTime":"10-19 09:39:43","open":8.06,"high":8.3,"low":8.04,"amount":22322500,"amplitude":0.0319,"askPrice":8.19,"askSize":1,"bidPrice":8.18,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.2989,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792380600000},"marketStatusCode":2,"adr":0,"adjPreClose":8.15,"symbolType":"stock","openAndCloseTimeList":[[1792373400000,1792380600000],[1792386000000,1792393200000]],"highLimit":8.97,"lowLimit":7.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1615651020,"isCdr":false,"pbRate":1.9,"roa":"--","peRate":27.400468,"roe":"2.69%","epsLYR":0.36,"committee":-0.293292,"marketValue":13232000000,"turnoverRate":0.0017,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-20。","floatMarketCap":13232000000},"requestUrl":"/m/hq/s/603707/wiki","defaultTab":"wiki","newsList":[{"id":"2675216513","title":"股市必读：健友股份（603707）10月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675216513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675216513?lang=zh_cn&edition=full","pubTime":"2026-10-15 02:19","pubTimestamp":1792001948,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘，健友股份报收于8.0元，上涨0.0%，换手率0.41%，成交量6.58万手，成交额5263.76万元。董秘最新回复投资者： 看到公司阿达木单抗新规格在美国获批了，公告里说跟修美乐可互换具体是什么意思？公司子公司Emerge Bioscience Pte. Ltd. 阿达木单抗注射液近期获美国FDA批准。该产品后续商业化落地节奏，将结合美国市场环境、渠道布局情况稳步推进。目前该产品尚未在美国开展上市销售，短期不会对公司经营业绩构成重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673012652","title":"股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673012652","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673012652?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:59","pubTimestamp":1791395947,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，健友股份报收于8.19元，上涨3.8%，换手率1.11%，成交量18.01万手，成交额1.46亿元。当日关注点交易信息汇总：9月30日主力资金净流入582.71万元，占总成交额3.98%。公司公告汇总：健友股份子公司阿达木单抗注射液获美国FDA批准，获批规格与修美乐注射液具有可互换性，BLA号为761216。该产品为生物类似药，商品名为YUSIMRY，此前由Coherus BioSciences持有，本次获批规格与已获批修美乐注射液具有可互换性。公司为此项目累计投入研发费用约13,866.67万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0046","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671487742","title":"健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671487742","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671487742?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:36","pubTimestamp":1790692580,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，健友股份报收于7.89元，较前一交易日下跌0.25%，最新总市值为127.47亿元。该股当日开盘7.95元，最高7.98元，最低7.81元，成交额达6336.19万元，换手率为0.5%。近日，健友股份发布关于子公司产品阿达木单抗注射液获得美国FDA批准的公告。公告显示，公司全资子公司Emerge Bioscience Pte. Ltd.收到美国FDA批件，其申报的阿达木单抗注射液获得批准，BLA号为761216。公司为此项目累计投入研发费用约13,866.67万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900040654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","603707","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670875258","title":"沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2670875258","media":"央广财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670875258?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:22","pubTimestamp":1790601766,"startTime":"0","endTime":"0","summary":"央广网北京9月28日消息（记者牛谷月）9月28日晚间，沪市（含科创板）超20家上市公司集中发布多项利好公告，内容涵盖股份回购增持、资产重组、药品获批、重大经营合同落地等。多家企业以真金白银彰显对自身长期发展的信心，同时披露业务拓展新进展，向市场传递积极信号。回购增持成为本次晚间公告的重头戏，共有12家公司发布相关方案或实施进展。其中，两家公司抛出全新回购预案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885425388.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885425388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0277","LU1969619763.USD","600690","LU0456827905.SGD","BK0175","BK0196","LU2580892862.HKD","603195","BK0187","BK0097","BK0209","SGXZ81163826.USD","BK0028","BK0188","600720","603296","BK0044","BK0000","LU0456846285.SGD","BK0259","SGXZ49509284.SGD","688251","BK0026","688349","601607","LU2148510915.USD","LU2097828805.USD","BK0067","LU1794554557.SGD","601117","BK0010","LU1580142542.USD","BK0020","BK0235","605303","603310","LU2097828474.EUR","BK0184","IE0005HP3H50.USD","BK0183","BK0012","BK0201","LU1720050803.USD","603707","688111","BK0231","LU2097828714.EUR","BK0015","688032","601126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280512","title":"健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280512","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670280512?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:36","pubTimestamp":1790584569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司香港健友实业有限公司(以下简称“香港健友”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的维生素B1注射液200mg/2mL(100mg/mL)的ANDA批准通知(ANDA号：213131)。新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0186","LABU","BK4588","BK0046","BK4585","603707","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409103","title":"股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409103?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:03","pubTimestamp":1790532193,"startTime":"0","endTime":"0","summary":"公司公告汇总健友股份关于全资子公司参与认购私募基金份额的公告南京健友生化制药股份有限公司全资子公司Emerge Bioscience Pte. Ltd.于2026年9月23日与SouthChina Yitai VCC签署协议，拟以自有资金认购其旗下子基金Whitestream Two的A1类参与份额，出资承诺金额为4,000万美元，初始实缴200万美元。基金期限为首次缴款日起8年，可延长3年，主要投资于生物医药领域。本次投资无需提交公司董事会及股东会审议，不构成关联交易或重大资产重组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","603707","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669998734","title":"健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669998734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669998734?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:15","pubTimestamp":1790259355,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，健友股份报收于7.7元，较前一交易日下跌2.65%，最新总市值为124.41亿元。该股当日开盘7.9元，最高7.93元，最低7.69元，成交额达6334.14万元，换手率为0.5%。近日，健友股份发布《关于全资子公司参与认购私募基金份额的公告》。本次投资无需提交公司董事会及股东会审议，不构成关联交易或重大资产重组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669643862","title":"股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669643862","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669643862?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:20","pubTimestamp":1790184022,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司Meitheal获美国FDA批准硫酸阿米卡星注射液新增南京健友场地生产，ANDA号064045，已投入研发费用约409.08万元。公司公告汇总健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告南京健友生化制药股份有限公司子公司Meitheal Pharmaceuticals Inc.收到美国FDA通知，其申报的硫酸阿米卡星注射液增加生产场地申请获批，批准在南京健友生化制药股份有限公司场地生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711242","title":"健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711242","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669711242?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:17","pubTimestamp":1790065020,"startTime":"0","endTime":"0","summary":"9月22日，健友股份(603707.SH)公告称，公司子公司Meitheal Pharmaceuticals Inc.近日收到美国FDA签发的硫酸阿米卡星注射液(500mg/2mL、1g/4mL)增加生产场地的批件，批准在南京健友生化制 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LABU","BK0239","603707","BK0046","BK0186","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667293476","title":"股市必读：健友股份（603707）9月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2667293476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667293476?lang=zh_cn&edition=full","pubTime":"2026-09-16 01:09","pubTimestamp":1789492151,"startTime":"0","endTime":"0","summary":"截至2026年9月15日收盘，健友股份报收于7.4元，下跌1.07%，换手率0.24%，成交量3.84万手，成交额2848.68万元。董秘最新回复投资者： 公司现有12条FDA认证的产线，这么多年每次FDA现场核查都顺利通过。当日关注点交易信息汇总：9月15日主力资金净流出80.15万元，占总成交额2.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0186","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648094","title":"健友股份：FDA认证产线支撑自有品种快速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648094","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667648094?lang=zh_cn&edition=full","pubTime":"2026-09-15 17:09","pubTimestamp":1789463366,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份09月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司现有12条FDA认证的产线，这么多年每次FDA现场核查都顺利通过。这种稳定合规的产能，在参与海外集采、和海外药企谈合作的时候，请问，对公司有哪些业绩层面的优势？能转化成哪些实实在在的订单和业务机会哪？本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500027213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366354","title":"每周股票复盘：健友股份（603707）子公司获FDA阿达木单抗新增产线批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366354","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366354?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:11","pubTimestamp":1788635469,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，健友股份报收于7.89元，较上周的7.81元上涨1.02%。本周，健友股份9月1日盘中最高价报8.38元。该产品为生物类似药，商品名为YUSIMRY，适应症包括类风湿关节炎、银屑病关节炎、克罗恩病等多种疾病。截至目前，公司为此项目投入研发费用约13,777.78万元。此次批准有助于丰富公司国际化产品管线，强化国际市场布局，可能对公司经营业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335978","title":"健友股份：股价受宏观环境、行业周期、市场情绪等多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664335978?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:00","pubTimestamp":1788516040,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份09月04日在投资者关系平台上答复投资者关心的问题。股价受宏观环境、行业周期、市场情绪等多重因素影响，属市场交易行为，公司无法干预。公司及管理层严格遵守证券法律法规，不存在操控或放任股价的情形。管理层始终聚焦主业，扎实推进海外拓展与创新管线研发，持续加强投资者沟通，以长期经营业绩夯实内在价值。二级市场存在波动风险，敬请您理性看待。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400032452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0186","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664233591","title":"健友股份：XTMAB‑16 已完成 II 期临床试验，2026年已正式进入 III 期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2664233591","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664233591?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:00","pubTimestamp":1788516040,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份09月04日在投资者关系平台上答复投资者关心的问题。另外，xtmab16目前还没正式进入3期吗？健友股份回复：尊敬的投资者您好，1、甘精胰岛素项目目前正按计划推进美国FDA申报工作，如若获批公司将及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400032454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0186","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843472","title":"股市必读：健友股份新发布《健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843472","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664843472?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:12","pubTimestamp":1788369133,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司获美国FDA批准阿达木单抗注射液增加南京生产场地，BLA号761216，累计研发投入约13,777.78万元。公司公告汇总健友股份关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告南京健友生化制药股份有限公司子公司Emerge Bioscience Pte. Ltd.收到美国FDA签发的阿达木单抗注射液增加生产场地的批件，批准在南京健友生化制药股份有限公司场地生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897006","title":"健友股份：覆盖研发、注册、生产、全球销售的注射剂全产业链一体化出海模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897006?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:12","pubTimestamp":1788340335,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份09月02日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664529758","title":"健友股份（603707）披露子公司获美国FDA阿达木单抗注射液增加生产场地注册批件，9月1日股价上涨5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664529758","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664529758?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:07","pubTimestamp":1788271637,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，健友股份报收于8.37元，较前一交易日上涨5.42%，最新总市值为135.23亿元。近日，健友股份发布关于子公司获得美国FDA阿达木单抗注射液增加生产场地注册批件的公告。公告显示，南京健友生化制药股份有限公司子公司Emerge Bioscience Pte. Ltd.收到美国FDA签发的阿达木单抗注射液增加生产场地的批件，批准在南京健友生化制药股份有限公司场地生产。截至目前，公司为此项目投入研发费用约13,777.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100042354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663042730","title":"股市必读：健友股份新发布《健友股份2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663042730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663042730?lang=zh_cn&edition=full","pubTime":"2026-08-31 03:17","pubTimestamp":1788117429,"startTime":"0","endTime":"0","summary":"健友股份关于更换公司财务负责人的公告南京健友生化制药股份有限公司于2026年8月27日召开第六届董事会第二次会议，审议通过更换财务负责人的议案，同意聘任陈腊梅女士为公司财务负责人，任期至第六届董事会任期届满。健友股份关于召开2026年半年度业绩说明会的公告南京健友生化制药股份有限公司将于2026年9月17日9:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果和财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603707","BK0186","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663137010","title":"每周股票复盘：健友股份（603707）Q2净利降51.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663137010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663137010?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:04","pubTimestamp":1788030253,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，健友股份报收于7.81元，较上周的7.96元下跌1.88%。业绩披露要点：2026年第二季度归母净利润9853.88万元，同比下降51.11%。股本股东变化截至2026年6月30日，健友股份股东户数为3.4万户，较3月31日减少1683.0户，减幅4.72%。健友股份于2026年8月27日宣布聘任陈腊梅女士为财务负责人，任期至第六届董事会任期届满。健友股份将于2026年9月17日9:00-10:00通过上证路演中心召开2026年半年度业绩说明会，介绍经营成果和财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663165490","title":"健友股份（603707）2026年中报简析：净利润同比下降34.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663165490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663165490?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:11","pubTimestamp":1787955095,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期健友股份发布2026年中报。根据财报显示，健友股份净利润同比下降34.48%。截至本报告期末，公司营业总收入19.26亿元，同比下降2.71%，归母净利润1.88亿元，同比下降34.48%。去年的净利率为14.57%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于健友股份2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792373986600,"stockEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.1058},{"period":"3month","weight":0.0316},{"period":"6month","weight":-0.1321},{"period":"1year","weight":-0.2116},{"period":"ytd","weight":-0.0859}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0127},{"period":"6month","weight":-0.0827},{"period":"1year","weight":-0.0511},{"period":"ytd","weight":-0.0636}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京健友生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34010人(较上一季度减少4.72%)","perCapita":"47505股","listingDate":"2017-07-19","address":"江苏省南京市浦口区高新开发区MA010-1号地","registeredCapital":"161565万元","survey":" 南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。","listedPrice":7.21},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健友股份,603707,健友股份股票,健友股份股票老虎,健友股份股票老虎国际,健友股份行情,健友股份股票行情,健友股份股价,健友股份股市,健友股份股票价格,健友股份股票交易,健友股份股票购买,健友股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}